These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. A CCL2-based fusokine as a novel biopharmaceutical for the treatment of CCR2-driven autoimmune diseases. Rafei M; Galipeau J Crit Rev Immunol; 2010; 30(5):449-61. PubMed ID: 21083526 [TBL] [Abstract][Full Text] [Related]
45. Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2. O'Boyle G; Brain JG; Kirby JA; Ali S Mol Immunol; 2007 Mar; 44(8):1944-53. PubMed ID: 17081610 [TBL] [Abstract][Full Text] [Related]
46. Differential responsiveness to constitutive vs. inducible chemokines of immature and mature mouse dendritic cells. Vecchi A; Massimiliano L; Ramponi S; Luini W; Bernasconi S; Bonecchi R; Allavena P; Parmentier M; Mantovani A; Sozzani S J Leukoc Biol; 1999 Sep; 66(3):489-94. PubMed ID: 10496320 [TBL] [Abstract][Full Text] [Related]
47. Ly6C Schloss MJ; Hilby M; Nitz K; Guillamat Prats R; Ferraro B; Leoni G; Soehnlein O; Kessler T; He W; Luckow B; Horckmans M; Weber C; Duchene J; Steffens S Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1640-1645. PubMed ID: 28663258 [TBL] [Abstract][Full Text] [Related]
48. The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice. Maus U; von Grote K; Kuziel WA; Mack M; Miller EJ; Cihak J; Stangassinger M; Maus R; Schlöndorff D; Seeger W; Lohmeyer J Am J Respir Crit Care Med; 2002 Aug; 166(3):268-73. PubMed ID: 12153956 [TBL] [Abstract][Full Text] [Related]
49. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Mahad D; Callahan MK; Williams KA; Ubogu EE; Kivisäkk P; Tucky B; Kidd G; Kingsbury GA; Chang A; Fox RJ; Mack M; Sniderman MB; Ravid R; Staugaitis SM; Stins MF; Ransohoff RM Brain; 2006 Jan; 129(Pt 1):212-23. PubMed ID: 16230319 [TBL] [Abstract][Full Text] [Related]
50. Post-BMT lung injury occurs independently of the expression of CCL2 or its receptor, CCR2, on host cells. Panoskaltsis-Mortari A; Hermanson JR; Taras E; Wangensteen OD; Charo IF; Rollins BJ; Blazar BR Am J Physiol Lung Cell Mol Physiol; 2004 Feb; 286(2):L284-92. PubMed ID: 14527928 [TBL] [Abstract][Full Text] [Related]
51. CCR2 acts as scavenger for CCL2 during monocyte chemotaxis. Volpe S; Cameroni E; Moepps B; Thelen S; Apuzzo T; Thelen M PLoS One; 2012; 7(5):e37208. PubMed ID: 22615942 [TBL] [Abstract][Full Text] [Related]
52. Blockade of CCL2/CCR2 signaling pathway prevents inflammatory monocyte recruitment and attenuates OVA-Induced allergic asthma in mice. Jiang S; Wang Q; Wang Y; Song X; Zhang Y Immunol Lett; 2019 Oct; 214():30-36. PubMed ID: 31454522 [TBL] [Abstract][Full Text] [Related]
53. The chemokine decoy receptor M3 blocks CC chemokine ligand 2 and CXC chemokine ligand 13 function in vivo. Martin AP; Canasto-Chibuque C; Shang L; Rollins BJ; Lira SA J Immunol; 2006 Nov; 177(10):7296-302. PubMed ID: 17082648 [TBL] [Abstract][Full Text] [Related]
54. The chemokine receptors ACKR2 and CCR2 reciprocally regulate lymphatic vessel density. Lee KM; Danuser R; Stein JV; Graham D; Nibbs RJ; Graham GJ EMBO J; 2014 Nov; 33(21):2564-80. PubMed ID: 25271254 [TBL] [Abstract][Full Text] [Related]